Clinical Care Options Hepatitis - HBVThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  3  4  

Highlights From AASLD 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Review the most clinically relevant new data from the 2009 AASLD conference on HCV, HBV, and complications of advanced liver disease. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 17, 2009 Category: Infectious Diseases Source Type: journals

Fixed-Dose Tenofovir/Emtricitabine Safe and Effective Option for the Treatment of Patients With Chronic Hepatitis B Infection and Decompensated Liver DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The safety profile and virologic, biochemical, and clinical efficacy outcomes were similar among patients treated with 48 weeks of tenofovir/emtricitabine, tenofovir monotherapy, or entecavir monotherapy in this randomized phase II study. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 5, 2009 Category: Infectious Diseases Source Type: journals

Beyond the Tip of the Iceberg: Strategies to Ensure Optimal HBV Screening, Diagnosis, and Initial TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Downloadable slides for use in your own noncommercial presentations highlight key data on selecting patients for HBV screening and evaluation and optimizing first-line treatment. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 5, 2009 Category: Infectious Diseases Source Type: journals

HCC Risk Remains High Following at Least 12 Months of Antiviral Therapy in Cirrhotic Patients With Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - A multivariate analysis identified cirrhosis, older age, and male sex as independent predictors of hepatocellular carcinoma incidence in patients receiving at least 12 months of oral antiviral therapy, most of which was lamivudine based. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 3, 2009 Category: Infectious Diseases Source Type: journals

Intrahepatic cccDNA Levels at End of Treatment With Peginterferon alfa-2a Plus Adefovir Predictive of SVR in Patients With Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Intrahepatic cccDNA levels at baseline were not prognostic for response to peginterferon alfa-2a plus adefovir therapy. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 2, 2009 Category: Infectious Diseases Source Type: journals

Entecavir Associated With High Response Rates Over 36 Months in Patients With HBeAg-Positive and HBeAg-Negative Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Virologic response rates with entecavir were highest among patients who were previously untreated and among those with HBeAg-negative disease or low baseline HBV DNA levels; high response rates were also observed among patients with precore mutations. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - November 2, 2009 Category: Infectious Diseases Source Type: journals

Increase in ALT to ≥ 2 Times ULN During Follow-up Correlates With Increasing Morbidity and Mortality Among HBeAg-Negative, HBsAg-Positive IndividualsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - October 27, 2009 Category: Infectious Diseases Source Type: journals

Early Peginterferon-Induced HBeAg Loss Associated With Higher Probability of HBsAg Loss and Sustained Undetectable HBV DNAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - October 27, 2009 Category: Infectious Diseases Source Type: journals

Early Peginterferon-Induced HBeAg Loss Associated With Higher Probability of HBsAg Loss and Sustained Undetectable HBV DNAEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - More than one third of patients with HBeAg loss within the first 32 weeks of therapy with peginterferon alfa-2b alone or in combination with lamivudine were negative for HBsAg at long-term follow-up 3 years later. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - October 20, 2009 Category: Infectious Diseases Source Type: journals

Increase in ALT to ≥ 2 Times ULN During Follow-up Correlates With Increasing Morbidity and Mortality Among HBeAg-Negative, HBsAg-Positive IndividualsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In this long-term follow-up study, higher maximal ALT level during follow-up of a mean of 13 years was associated with increased risk of development of cirrhosis and liver-related mortality among HBeAg-negative, HBsAg-positive individuals. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - October 15, 2009 Category: Infectious Diseases Source Type: journals

Benefits and Risks of HBV TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - July 31, 2009 Category: Infectious Diseases Source Type: journals

Treatment of Hepatitis B: Benefits and Risks of Hepatitis B TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - July 31, 2009 Category: Infectious Diseases Source Type: journals

HBV Infection: Deciding Who and When to TreatEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Anna S. F. Lok, MD, discusses factors to consider when evaluating patients with chronic hepatitis B infection for initiating treatment. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - July 10, 2009 Category: Infectious Diseases Source Type: journals

Advances in HBV Treatment: 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Join Maria Buti, MD; Anna S. F. Lok, MD; and Patrick Marcellin, MD, as they review and discuss the latest data on the treatment of chronic HBV infection presented at the 2009 European Association for the Study of the Liver annual meeting. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - June 17, 2009 Category: Infectious Diseases Source Type: journals

Management of Initial HBV Therapy for an HBeAg-Negative PatientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Attempt this Interactive Case Challenge and learn strategies for frontline regimen selection and on-treatment management of patients with HBeAg-negative chronic HBV infection with Calvin Q. Pan, MD, FACP, FACG. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - June 9, 2009 Category: Infectious Diseases Source Type: journals

HBV Treatment: What to Start?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Robert G. Gish, MD, describes the latest data and reviews the most recent guidelines on the optimal selection of first-line therapy for patients with chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 29, 2009 Category: Infectious Diseases Source Type: journals

HBV Treatment: What to Start?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slide highlights from the CME-certified module on initial HBV therapies for self study and use in your own presentations. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 29, 2009 Category: Infectious Diseases Source Type: journals

Tenofovir Demonstrates Superior Efficacy, Similar Safety vs Adefovir in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 28, 2009 Category: Infectious Diseases Source Type: journals

Managing Initial Treatment for an Asian American Patient With HBeAg-Positive Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Learn about frontline regimen selection and on-treatment management of an HBeAg-positive patient and apply this learning with Albert D. Min, MD, in this Interactive Case Challenge. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 28, 2009 Category: Infectious Diseases Source Type: journals

Tenofovir Demonstrates Superior Efficacy, Similar Safety vs Adefovir in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In 2 randomized trials, HBeAg-positive and HBeAg-negative patients receiving tenofovir for 48 weeks achieved higher rates of HBV DNA suppression vs adefovir and significantly more HBeAg-positive patients achieved ALT normalization and HBsAg loss with tenofovir vs adefovir. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 27, 2009 Category: Infectious Diseases Source Type: journals

Early HBsAg Loss Predicts SVR in HBeAg-Negative Patients Treated With Peginterferon alfa-2aEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 7, 2009 Category: Infectious Diseases Source Type: journals

Early HBsAg Loss Predicts SVR in HBeAg-Negative Patients Treated With Peginterferon alfa-2aEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In a prospective study, > 0.5 log10 IU/mL decrease in HBsAg at Week 12 or > 1.0 log10 IU/mL decrease at Week 24 had high predictive value for subsequent SVR in HBeAg-negative patients treated with peginterferon alfa-2a. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - May 4, 2009 Category: Infectious Diseases Source Type: journals

Equivalent Efficacy of Tenofovir/Emtricitabine vs Tenofovir Monotherapy Through Week 96 in Patients With HBV and Persistent Viremia on AdefovirEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Baseline adefovir and lamivudine resistance mutations did not impair subsequent Week 96 response to tenofovir +/- emtricitabine. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 26, 2009 Category: Infectious Diseases Source Type: journals

Viral Suppression Maintained in Subset of HBeAg-Positive and HBeAg-Negative Patients Without Evidence of Genotypic Resistance After 2 Years of Telbivudine Who Continued Treatment Through 3 YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Undetectable HBV DNA at treatment Week 24 associated with improved long-term (3 years) virologic, biochemical, and serologic outcomes vs patients with detectable Week 24 HBV DNA. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 26, 2009 Category: Infectious Diseases Source Type: journals

High Risk of Peripheral Neuropathy Associated With Telbivudine Plus Peginterferon alfa-2a vs Telbivudine MonotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Combination of peginterferon alfa-2a and telbivudine not recommended due to increased rates of peripheral neuropathy. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 26, 2009 Category: Infectious Diseases Source Type: journals

Tenofovir Highly Effective for the Treatment of Chronic HBV Infection in Both Cirrhotic and Noncirrhotic PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Virologic, biochemical, and immunologic response rates were statistically similar among cirrhotic vs noncirrhotic patients treated with 96 weeks of tenofovir. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 24, 2009 Category: Infectious Diseases Source Type: journals

Entecavir Resistance Rare in Nucleoside-Naive HBV Patients Through 6 YearsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Entecavir resistance rare in treatment-naive patients but common at Year 6 in patients with lamivudine-refractory HBV. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 24, 2009 Category: Infectious Diseases Source Type: journals

Superior HBV Seroprotection With 2-Dose Combination HBsAg-1018 Immunostimulatory Sequence Vaccine vs Currently Approved HBV VaccineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - A higher rate of seroprotection was achieved with the HBsAg-1018 immunostimulatory sequence vs the standard HBV vaccine, even among participants aged 40-55 years. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 17, 2009 Category: Infectious Diseases Source Type: journals

HBsAg Levels Reduced by Telbivudine Treatment in HBeAg-Positive Patients With Chronic Hepatitis B From GLOBE StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Rapid HBsAg decline during the first year of telbivudine therapy predictive of a high rate of HBsAg clearance at Year 3. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 17, 2009 Category: Infectious Diseases Source Type: journals

Long-term Sustained Response and HBsAg Loss After Discontinuation of 4-5 Years of Adefovir Therapy in HBeAg-Negative PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - More than one half of HBeAg-negative patients sustained response to long-term adefovir therapy for > 4 years after treatment discontinuation. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 17, 2009 Category: Infectious Diseases Source Type: journals

No Increased Risk of Birth Defects Associated With Prenatal Lamivudine or Tenofovir Exposure In Antiretroviral Pregnancy Registry StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Birth defect rates were similar with first vs second/third trimester exposure to antiretrovirals in the Antiretroviral Pregnancy Registry cohort. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 17, 2009 Category: Infectious Diseases Source Type: journals

Entecavir Efficacy Not Affected by Previous Adefovir Treatment or Resistance in Chronic HBV–Infected PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Virologic response rate to entecavir significantly lower in patients with lamivudine resistance vs those without. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - April 17, 2009 Category: Infectious Diseases Source Type: journals

Clinical Utility of ALT in Diagnosis and Management of Chronic Hepatitis BEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Virtual Presentation - W. Ray Kim, MD, discusses the importance of ALT in hepatitis B and outlines management approaches for patients with normal ALT levels. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - March 6, 2009 Category: Infectious Diseases Source Type: journals

Preventing Nucleos(t)ide Resistance in Treatment-Naive PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Marc G. Ghany, MD, discusses oral agents for the treatment of chronic hepatitis B, their potency, and barriers to resistance and how this impacts the selection of initial treatment regimens. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - March 5, 2009 Category: Infectious Diseases Source Type: journals

New Management Strategies for HCV Nonresponders and RelapsersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Mitchell L. Shiffman, MD, reviews the various types of virologic response in patients treated for hepatitis C virus infection, discusses what factors are associated with better responses, and summarizes the most recent data available on various retreatment strategies. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Tools for the Assessment of HBV Resistance in Clinical PracticeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Dr. Fabien Zoulim describes assays for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

A Practical Guide to Management of Patients With Antiviral Drug-Resistant HBVEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Anna S. F. Lok, MD, discusses the definitions, consequences of, and treatment strategies for HBV drug resistance. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Management of a Treatment-Naive, HBeAg-Positive, Asian American PatientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Hepatitis Journal Club: Top Clinical Articles of 2007-08Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Management of a 52-Year-Old HBeAg-Positive, Treatment-Naive Female Seeking Hepatitis B TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Robert G. Gish, MD, reviews the importance of HBV DNA in determining treatment candidacy and making on-treatment decisions in hepatitis B management in this interactive case challenge. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Management of Emergent Depression and Suicidal Ideation During HCV TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Case Challenge - Join Alfredo Alberti, MD, in choosing the optimal treatment strategies for a woman who develops depressive symptoms during HCV therapy, despite the absence of symptoms at treatment baseline. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Management of Hepatitis B: Understanding Treatment Candidacy and Factors for Selecting Initial TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - February 9, 2009 Category: Infectious Diseases Source Type: journals

Mechanisms of Resistance to Anti-HBV AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Maria Buti, MD, reviews the development of HBV antiviral resistance in context of the life cycle of HBV and the mechanisms of action of antiviral drugs. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - January 28, 2009 Category: Infectious Diseases Source Type: journals

HBV HighlightsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - This downloadable slideset reviews key hepatitis B data from the 2008 AASLD meeting and shows how these data relate to the current management of hepatitis B. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - January 14, 2009 Category: Infectious Diseases Source Type: journals

Focus on Investigational HBV/HCV AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Join Nezam H. Afdhal, MD, FRCPI; Fred Poordad, MD; and Stefan Zeuzem, MD, as they discuss novel agents being developed for the treatment of chronic HBV and HCV infections. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - January 5, 2009 Category: Infectious Diseases Source Type: journals

HBV Expert Recap of AASLD 2008Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - Watch and listen as Nezam H. Afdhal, MD, FRCPI, reviews the key clinical data on hepatitis B investigational and approved agents presented at the 2008 AASLD meeting. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - January 2, 2009 Category: Infectious Diseases Source Type: journals

Advances in HBV Treatment With Approved AgentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Join Jules L. Dienstag, MD; Robert G. Gish, MD; and Ira M. Jacobson, MD, as they discuss data presented at the 2008 AASLD Meeting on advances in the use of currently approved therapies for the treatment of chronic hepatitis B infection. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - December 17, 2008 Category: Infectious Diseases Source Type: journals

Journal Options SlidesetEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - December 16, 2008 Category: Infectious Diseases Source Type: journals

HBeAg Loss Induced by Peginterferon alfa-2b ± Lamivudine Treatment Sustained Over Long-term Follow-upEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Long-term follow-up demonstrates sustained HBeAg negativity with high rate of HBsAg loss following peginterferon alfa-2b therapy; genotype A HBV associated with significantly higher rate of HBsAg loss. (Source: Clinical Care Options Hepatitis - HBV)
Source: Clinical Care Options Hepatitis - HBV - December 15, 2008 Category: Infectious Diseases Source Type: journals